Reaction mass of [5-methyl-2-[[4-(4-methylanilino)-9,10-dioxo-1-anthryl]amino]phenyl]sulfonyloxypotassium and [5-methyl-2-[[4-(4-methyl-2-potassiooxysulfonyl-anilino)-9,10-dioxo-1-anthryl]amino]phenyl]sulfonyloxypotassium

Endpoint summary

Description of key information

Oral LD50 (male and female) > 2000 mg/kg bw

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

From 18 December, 1990 to 18 January, 1991

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

test procedure in accordance with generally accepted scientific standards and described in sufficient detail

Justification for type of information:

The read across approach is detailed into the document attached to the IUCLID section 13.

Reason / purpose for cross-reference:

read-across source

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Version / remarks:

adopted in 1981

Qualifier:

according to guideline

Guideline:

EU Method B.1 (Acute Toxicity (Oral))

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River (UK) Ltd., Manston, Kent, U.K.
- Age at study initiation: at the start of the main study, rats were approximately five to eight weeks old.
- Weight at study initiation: at the start of the main study, males 170 - 200 g and females 143 - 157 g.
- Fasting period before study: overnight fast immediately before dosing and for approximately two hours after dosing.
- Housing: the animals were housed in groups of up to five by sex in solid-floor polypropylene cages with sawdust bedding.
- Diet: Rat and Mouse Expanded Diet No. l (Special Diet Services Limited) was allowed throughout the study.
- Water: free access to mains drinking water.
- Acclimation period: a minimum period of at Ieast five days.

ENVIRONMENTAL CONDITIONS
- Temperature: 17 - 21 °C. On occasions the temperature was below the Iower Iimit specified in the protocol (19 °C). This did not affect the purpose or integrity of the study.
- Humidity: 42 - 62 %
- Air changes : approximately 15 changes per hour.
- Photoperiod: 12 hours continuous Iight and 12 hours darkness.

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

For the purpose of the study the test material was freshly prepared, as required, as a suspension at the appropriate concentration in distilled water.
The composition and stability of the test material and the stability of the preparations were not determined.
- Dose volume: 10 ml/kg
- Concentration: 200 mg/ml

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5 males and 5 females

Details on study design:

MAIN EXPERIMENT
- Duration of observation period following administration: 14 days
- Frequency of observations: deaths and overt signs of toxicity were recorded 1/2, 1, 2 and 4 hours after dosing and then daily for 14 days.
- Frequency of weighing: individual bodyweights were recorded on the day of treatment (day 0) and on days 7 and 14 or at death.
- Necropsy of survivors performed: yes; at the end of the study the animals were killed by cervical dislocation. The abdominal and thoracic cavities were opened for examination of all major organs. The macroscopic appearance of any abnormal organs was recorded. No tissues were retained.

DOSE RANGE-FINDING
- Dose levels: 5000, 2000 and 200 mg/kg bw.
- No of animals per dose: 1 male and 1 female.
- Observations: deaths and overt signs of toxicity were recorded 1/2, 1, 2 and 4 hours after dosing and then daily for five days. Individual bodyweights were recorded on the day of dosing to allow calculation of individual treatment volumes. No necropsies were performed.

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

not determinable due to absence of adverse toxic effects

Mortality:

MAIN EXPERIMENT
One female was found dead approximately six hours after dosing.

DOSE RANGE-FINDING
One male treated with 5000 mg/kg was found dead one day after treatment.

Clinical signs:

MAIN EXPERIMENT
Isolated incidents of toxicity noted during the study were hunched posture and lethargy.
Purple-coloured staining of the fur was commonly noted during the study.

DOSE RANGE-FINDING
Signs of toxicity noted were hunched posture, lethargy and ptosis. Purple-coloured staining of the fur was also noted.

Body weight:

MAIN EXPERIMENT
Surviving animals showed expected gain in bodyweight during the study.

Gross pathology:

MAIN EXPERIMENT
Abnormalities noted at necropsy of the female that died during the study were abnormally red lungs, dark liver and dark kidneys.
No abnormalities were noted at necropsy of animals killed at the end of the study.

Interpretation of results:

other: not classified, according to the CLP Regulation (EC) No 1272/2008

Conclusions:

LD50 (male and female) > 2000 mg/kg bw

Executive summary:

The study was performed to assess the acute oral toxicity of the test material in the Sprague-Dawley strain rat. The method used followed the recommendations of the OECD Guidelines for Testing of Chemicals (1981) No. 401 "Acute Oral Toxicity" referenced as Method B1 in Commission Directive 84/449/EEC (which constitutes Annex V of Council Directive 67/548/EEC).

Based on the results of the dose range finding experiment, 5 males and 5 females were treated at a dosage level of 2000 mg/kg bw. The substance was administered as a single dose by gavage. After administration of the compound, the animals were observed for 14 days; at the end of the observation period, surviving animals were killed and an autopsy performed.

One female was found dead approximately six hours after dosing; abnormalities noted at necropsy of the female that died during the study were abnormally red lungs, dark liver and dark kidneys.

Isolated incidents of toxicity noted during the study were hunched posture and lethargy. Purple-coloured staining of the fur was commonly noted during the study. Surviving animals showed expected gain in bodyweight during the study. No abnormalities were noted at necropsy of animals killed at the end of the study.

Conlcusion

LD50 (male and female) > 2000 mg/kg bw

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

ACUTE TOXICITY BY ORAL ROUTE

A sheet reporting the test results of an old experiment conducted on Acid Green 025 is available; however, due to the fact that details on testing procedures and results are lacking, a reliability cannot be assiged. The result is here mentioned for completeness sake. The oral LD50 inrat was indicated to be higher than 5000 mg/kg bw (reference 1976).

In order to assess the oral acute potential toxicity of Acid Green 025, the available information on the structural analogous Similar Substance 02 have been taken into consideration; the read across approach can be considered as appropriate and suitable to assess the property under investigation (details about the approach are reported into the IUCLID section 13).

The study was performed to assess the acute oral toxicity of the Similar Substance 02 in the Sprague-Dawley strain rat. The method used followed the recommendations of the OECD Guidelines 401. Based on the results of the dose range finding experiment, 5 males and 5 females were treated at a dosage level of 2000 mg/kg bw. The substance was administered as a single dose by gavage. One female was found dead approximately six hours after dosing; abnormalities noted at necropsy of the female that died during the study were abnormally red lungs, dark liver and dark kidneys. Isolated incidents of toxicity noted during the study were hunched posture and lethargy. Purple-coloured staining of the fur was commonly noted during the study. Surviving animals showed expected gain in bodyweight during the study. No abnormalities were noted at necropsy of animals killed at the end of the study.

INHALATION ACUTE TOXICITY

No acute toxicity studies by inhalation route are available on Acid Green 025.

Nevertheless, because of the physical state of the substance inhalation is expected to be a negligible route of exposure. Particle size distribution showed that ca 90 % of particles has a diameter higher than 10 μm and that less than 3 % of particles have a diameter lower than 4 μm; the median D50 resulted to be 133.6 μm. Thus, most of the Acid Green 025 particles are expected to remain in the upper respiratory tract, which is characterized by efficacious defence mechanisms able to remove them; respirable particles, able to enter the deepest part of the lung, the non-ciliated alveoli (i.e. 4 μm), can be considered a minimal portion. This consideration, together with the consideration that the substance is manufactured and handled with suitable risk management measures and with the suitable personal protective equipments, lets to consider the possible absorption of the substance by inhalation route as negligible.

DERMAL ACUTE TOXICITY

According to the Commission Regulation (EU) 2016/863, amending Annexes VII and VIII to REACH Regulation (EC) No 1907/2006, testing by the dermal route does not need to be conducted if no systemic effects have been observed in in vivo studies with dermal exposure (e.g. skin irritation, skin sensitisation). Furthermore, it is explained that recent scientific analysis of available data from in vivo acute toxicity studies have shown that substances that are not toxic via the oral route may be expected with high certainty to be also non-toxic via the dermal route. The amendment is the consequence of studies and scientific debates. In particular, the 15^th Meeting of Competent Authorities for REACH and CLP (CARACAL, 2014) concluded that an adaptation of point 8.5.3 of Annex VIII to REACH is justified in order to not require information on acute dermal toxicity for substances that have shown no toxicity in acute oral toxicity test up to the limit dose of 2000 mg/kg bw.

In the oral acute toxicity test, no signs of systemic toxicity were recorded, as well as in the investigation performed with the analogous Similar Substance 01 on the skin sensitisation potential. Furthermore, no reason of concern is raised on the basis of the skin/eye irritation investigations.

Therefore, the substance is expected to be hot harmful/toxic by dermal route.

REFERENCE

Reference, 1976 - See attachement

CARACAL, 2014. 15th Meeting of Competent Authorities for REACH and CLP (CARACAL), 8 – 9 July 2014. Charlemagne building, Brussels, Belgium. Brussels, 26 July 2014. Doc. CA/61/2014. Stakeholder proposal to modify REACH standard information requirements for acute toxicity (REACH Annex VIII, point 8.5)

Justification for classification or non-classification

According to the CLP Regulation (EC) No 1272/2008, 3.1 Acute toxicity section, substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).

The oral LD50 value was established to be greater than 2000 mg/kg body weight, therefore the test substance is out of any classification limit for acute oral toxicity (oral acute toxicity category 4: 300 < ATE ≤ 2000 mg/kg bw).

On the basis of the physicochemical and toxicological information available, there are no reasons to suspect any concern for acute toxicity potential by both dermal and inhalation routes.

In conclusion, the substance does not meet the criteria to be classified as harmful/toxic if swallowed, according to the CLP Regulation (EC) No 1272/2008 .